Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 977-986

  Smith Palmer, J ^a   Fajardo Montanana C ^b   Pollock, R F ^a   Ericsson, A ^c   Valentine, W J ^a  

^a Ossian Health Economics and Communications GmbH   (Switzerland)

^b HOSPITAL DE LA RIBERA   (Spain)

^c Novo Nordisk Scandinavia   (Sweden)

Author keywords

Cost effectiveness; Insulin detemir; Sweden; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN;

ARTICLE; BLINDNESS; BODY MASS; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE DURATION; DRUG COST; FOOT ULCER; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STROKE; SWEDEN; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SWEDEN; TREATMENT OUTCOME;

EID: 84865249409     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.692340     Document Type: Article

References (33)

1. Ringborg A, Lindgren P, Martinell M, et al. Prevalence and incidence of Type 2 diabetes and its complications 1996-2003-estimates from a Swedish population-based study. Diabet Med 2008;25:1178-86
2. Jansson SP, Andersson DK, Svärdsudd K. Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up. Diabetologia 2007;50:703-10
3. Eliasson B, Cederholm J, Nilsson P, et al; Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 2005;22:1420-6
4. Bolin K, Gip C, Mörk AC, et al. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005-A register-based approach. Diabet Med 2009;26:928-34
5. Fajardo-Montan ana C, Herná ndez Herrero C, Rivas Ferná ndez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: The PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23
6. Garber AJ, Clauson P, Pedersen CB, et al. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials. J Am Geriatr Soc 2007;55:1735-40
7. Valentine WJ, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: A modelling study of long-term clinical and cost outcomes. Adv Ther 2008;25:567-84
8. Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-90
9. Tunis SL, Minshall ME, Conner C, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin 2009;25:1273-84
10. Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term costeffectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health 2011;39:79-87
11. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5-S26.
12. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20:S27-S40
13. Farnkvist LM, Lundman BM. Outcomes of diabetes care: A population-based study. Int J Qual Health Care 2003;15:301-7
14. Palmer JL, Goodall G, Nielsen S, et al. Cost-effectiveness of insulin as part versus human soluble insulin in type 2 diabetes in four European countries: Subgroup analyses from the PREDICTIVE study. Curr Med Res Opin 2008;24:1417-28
15. Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:387-96
16. Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the longterm health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869-76
17. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-9
18. Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, et al; Swedish National Diabetes Register (NDR). Risk factor control in patients with Type 2 diabetes and coronary heart disease: Findings from the Swedish National Diabetes Register (NDR). Diabet Med 2009;26:53-60
19. Gerdtham UG, Clarke P, Hayes A, et al. Estimating the cost of diabetes mellitusrelated events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics 2009;27:81-90
20. Henriksson F. Applications of economic models in healthcare: The introduction of pioglitazone in Sweden. Pharmacoeconomics 2002;20(1 Supp):43-53
21. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
22. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10:43-55
23. Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767-78
24. World Economic Outlook Database. International Monetary Fund. 2010. http://www.imf.org/external/pubs/ft/weo/2010/01/weodata/weorept.aspx? sy1998&ey2010&scsm1&ssd1&sortcountry&ds.&br1&pr1. x-41&pr1.y7&c144&sPCPI,PCPIPCH&grp0&a. Accessed December 6, 2010
25. Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data. Int J Clin Pract 2008;62:708-16
26. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
27. Australian Institute of Health and Welfare. The burden of disease and injury in Australia. Australian Institute of Health and Welfare, 2003
28. Tengs TO, Wallace A. One thousand health-related quality-of life estimates. Med Care 2000;38:583-637
29. Carrington AL, Mawdsley SK, Morley M, et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996;32:19-25
30. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;29:73
31. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
32. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. LFNAR 2003;2:1-3. http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf. Accessed February 18, 2011
33. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43